OTC omega-3 fish oil (mixed EPA+DHA) has shown inconsistent cardiovascular benefit in large trials including ORIGIN and ASCEND, contrasting with pure EPA (Vascepa). Evidence suggests mixed formulations may partially offset EPA benefits via DHA competition.
Research summaries are AI-generated from open-access peer-reviewed literature (PubMed Central, Cochrane, AHA/ACC). Content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.